Trial Profile
Niacin, N-3 fatty acids and insulin resistance.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2021
Price :
$35
*
At a glance
- Drugs Niacin (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Hypertriglyceridaemia
- Focus Pharmacodynamics; Therapeutic Use
- 27 Jan 2011 Status changed from recruiting to completed.
- 22 Apr 2008 The expected completion date for this trial is now 1 Dec 2008.
- 01 Oct 2006 New trial record.